

Coronavirus disease-19 pneumonia: The impact of coagulopathy

Neumonía por COVID-19: el impacto de la coagulopatía

Luca Costanzo^{1*}, Giacomo Failla¹, Simona A. Grasso², Francesco P. Palumbo³, Giorgio Ardit¹, Luigi Di-Pino⁴, Francesco Mugno¹, Paolo Finocchiaro¹, Leonardo Aluigi⁵, and Pier Luigi-Antignani⁶

¹Department of Cardiovascular Disease, Angiology Unit, San Marco Hospital A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Catania;

²Department of Anesthesia and Intensive Care, AOU Policlinico Vittorio Emanuele, Catania; ³Surgery Unit, Villa Fiorita Clinic, Prato; ⁴Department of Cardiovascular Disease, Cardiology and Angiology C.A.S.T., A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Catania; ⁵Angiology, Care Unit Villalba, Bologna; ⁶Vascular center, Nuova Villa Claudia, Rome. Italy

Abstract

The development of coagulopathy is emerging as one of the most significant poor prognostic features in coronavirus disease (COVID)-19 pneumopathy. D-dimer, a protein product of fibrin degradation, has been found elevated in the most severe cases and correlated to mortality. Potentially involved factors in the impairment of coagulation caused by viral infection include the dysregulated inflammatory response, platelet, and endothelial dysfunction with impaired fibrinolysis. Heparin is an anti-coagulant molecule that also showed anti-inflammatory properties and a potential antiviral effect. The use of low-molecular-weight heparin could prevent thromboembolic complications in COVID-19 pneumopathy. However, the correct timing of prophylaxis according to the stage of COVID-19 disease and the appropriate therapeutic dosage to use in severe cases needs further researches.

Key words: Coronavirus disease-19. Thrombosis. Coagulopathy. D-dimer. Low-molecular-weight heparin.

Resumen

El desarrollo de coagulopatía se reconoce como una de las complicaciones y características clínicas más significativas asociadas a un pronóstico desfavorable en la neumopatía por enfermedad por coronavirus (COVID)-19. El dímero D, un producto proteico de la degradación de la fibrina se ha encontrado elevado en los casos más graves y correlacionado con elevación en la mortalidad. Los factores potencialmente involucrados en el deterioro de la coagulación causada por una infección viral incluyen una respuesta inflamatoria desregulada, las plaquetas y la disfunción endotelial con fibrinolisis alterada. La heparina es una molécula anticoagulante que también ha mostrado propiedades antiinflamatorias y un posible efecto antiviral. El uso de heparina de bajo peso molecular podría prevenir complicaciones tromboembólicas en la neumopatía por COVID-19; sin embargo, el momento correcto de la profilaxis de acuerdo con la etapa de la enfermedad COVID-19 y la dosis terapéutica adecuada para usar en casos severos requiere todavía más investigación.

Palabras clave: COVID-19. Trombosis. Coagulopatía. Dímero D. Heparina de bajo peso molecular.

Correspondence:

*Luca Costanzo

E-mail: lucacost84@gmail.com

Date of reception: 05-06-2020

Date of acceptance: 10-06-2020

DOI: 10.24875/RMA.M20000013

Available online: 21-07-2020

Rev Mex Angiol. 2020;48(2):35-37

www.RMAngiologia.com

0377-4740/© 2020 Sociedad Mexicana de Angiología y Cirugía Vascular y Endovascular, A.C. Published by Permanyer México. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

In December 2019 in the city of Wuhan, China, a novel coronavirus infection (coronavirus disease [COVID]-19) developed causing significant mortality in many countries and becoming a pandemic disease¹. The main symptoms of COVID are related to respiratory involvement that in the most severe cases worsen to acute respiratory distress syndrome (ARDS) and systemic disease with multiorgan failure². In such a clinical scenario, the activation of the coagulation system with thromboembolic manifestations has been described³. Recently, 31% incidence of thrombotic complications in intensive care unit patients with COVID-19 has been reported despite systematic thrombosis prophylaxis. The most frequent complication was pulmonary embolism (81%), however, arterial thrombotic events occurred in 3.7% of patients⁴. Moreover, the development of disseminated intravascular coagulation (DIC) has been described by Tang et al. Indeed, they found alterations in laboratory parameters according to diagnostic criteria for DIC on 15 (71.4%) deaths by COVID-19 disease³.

Several factors could be involved in the impairment of coagulation caused by COVID-19: the dysregulated immune response that triggers the activation of coagulation cascade, thrombocytopenia, endothelial dysfunction, and impaired fibrinolysis.

Dysregulated immune response

The viral infection induces an inflammatory state through the activation of endothelial cells, platelets, and leukocytes⁵. A “cytokines storm” with overexpression of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha has been described during viral infection⁶. The severe inflammatory response induces a procoagulant state through the expression of tissue factor and von Willebrand factor. Result is the activation of the coagulation cascade with final generation of fibrin. In SARS-CoV infection, evidence of fibrin clots in the alveoli has been found⁷. Fibrin accumulation in the lung is a hallmark of acute lung injury and ARDS, and a reduced capacity to cleave and remove fibrin deposits corresponded to a poor clinical patient outcome⁸. Similar findings have been described in patients who died from COVID-19 disease. Histopathological examination revealed fibrin exudation in alveoli and, notably, formation of hyaline thrombus in small vessels in other organs and tissues⁹.

Thrombocytopenia and platelet dysfunction

In viral infections, platelet dysfunction, destruction, or a reduced platelets production have been reported⁵.

A recent meta-analysis of nine studies including nearly 400 patients with severe COVID-19 disease identified that the platelet count was significantly lower in severe cases¹⁰. Although pathogenesis of thrombocytopenia in COVID-19 disease has not been fully clarified, thrombocytopenia caused by autoantibodies and a reduced platelets production has been described in other respiratory infections such as SARS-CoV and influenza^{5,11}. Another described mechanism is the binding of the virus to platelets followed by their activation, exposure of P- selectin on the platelet surface that triggers the formation of platelet-leukocyte aggregates. Subsequently, endothelial cells are activated and an increase in von Willebrand factor can be found⁵.

Endothelial dysfunction and impaired fibrinolysis

Endothelial cells play a crucial role in the regulation of coagulation, both producing and presenting anticoagulant markers and procoagulant factors.

The direct endothelial cells involvement in COVID-19 could be hypothesized because the virus accesses host cells through the protein angiotensin-converting enzyme 2¹² that is also expressed by endothelial cells¹³. Viral infection activates endothelial cells causing the activation of coagulation that is mainly marked by an increase in von Willebrand factor secretion, which can bind platelets after vessel wall damage¹⁴.

In COVID-19 infection, fibrinolysis can be impaired and the pathogenesis could be the same as SARS. In this infection, increased levels of plasminogen activator inhibitor-1 and increased plasma concentrations of tissue plasminogen activator and soluble thrombomodulin were found^{15,16}.

Role of anticoagulation as a therapy for COVID-19

As discussed before, COVID-19 infection could cause a coagulopathy through severe inflammatory state, endothelial dysfunction, and impaired fibrinolytic activity. Therefore, anticoagulant therapy is emerging as one potential adjunctive treatment for COVID-19 disease.

Heparins are anticoagulant drugs used for the prophylaxis and therapy of venous thromboembolism. In a retrospective analysis conducted by Tang et al. on 449 Chinese patients affected by severe COVID-19,

a favorable outcome was reported thanks to the use of heparin. In particular, 94 patients received low-molecular-weight heparin (LMWH, 40-60 mg enoxaparin/day) and 5 received unfractionated heparin (UFH, 10,000-15,000 U/day). Heparin therapy significantly reduced mortality in patients with sepsis-induced coagulopathy (SIC) score ≥ 4 but not in those with SIC score $< 4^{17}$. Apart from the well-known anticoagulant action, anti-inflammatory properties have also postulated: binding with inflammatory cytokines, inhibition of neutrophil chemotaxis and leukocyte migration, and antagonization of histones released from damaged cells¹⁸⁻²⁰. A potential antiviral role has been questioned and an interaction with the binding domain of the spike S1 SARS-CoV-2 protein receptor has been recently investigated²¹. In summary, heparin could protect from thrombotic complications, microcirculatory dysfunction and possibly decrease multiorgan damage. However, large-size studies and higher-quality data are lacking to provide definitive indications for anticoagulant use. Future researches should focus on how COVID-19 infection triggers thrombotic diseases in some patients while in most of cases, infection remains asymptomatic, what are the patient's clinical characteristics that raise thrombotic risk, who benefits from early thrombotic prophylaxis, who needs to continue the treatment after hospital discharge, what is the appropriate dose of heparin, and how to monitor efficacy of anticoagulant treatment.

Acknowledgments

The authors express their gratitude to Monica Grasso for her assistance in revision of the English text.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J Autoimmun*. 2020;109:102433.
2. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*. 2020;368:m1091.
3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost*. 2020;18:844-7.
4. Klok FA, Kruij JP, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020;191:145-7.
5. Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VE, Meijers JC, et al. review: viral infections and mechanisms of thrombosis and bleeding. *J Med Virol*. 2012;84:1680-96.
6. Opal SM. Interactions between coagulation and inflammation. *Scand J Infect Dis*. 2003;35:545-54.
7. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. *J Pathol*. 2015;235:185-95.
8. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Mauder RJ, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. *J Clin Invest*. 1989;84:695-705.
9. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. *Zhonghua Bing Li Xue Za Zhi*. 2020;49:411-7.
10. Lippi G, Plebani M, Michael HB. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. *Clin Chim Acta*. 2020;506:145-8.
11. Yang M, Ng MH, Li CK. Thrombocytopenia in patients with severe acute respiratory syndrome (review). *Hematology*. 2005;10:101-5.
12. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med*. 2020;46:586-90.
13. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004;203:631-7.
14. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. *J Thromb Haemost*. 2003;1:1335-42.
15. Liu ZH, Wei R, Wu YP, Lisman T, Wang ZX, Han JJ, et al. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. *Biomed Environ Sci*. 2005;18:260-4.
16. Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, et al. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. *Thromb Haemost*. 2006;96:100-1.
17. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *J Thromb Haemost*. 2020;18:1094-9.
18. Mousavi S, Moradi M, Khorshidahmad T, Motamed M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. *Adv Pharmacol Sci*. 2015;2015:507151.
19. Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. *Pharmaceuticals* 2016;9:38.
20. Iba T, Hashiguchi N, Nagaoka I, Tabe Y, Kadota K, Sato K. Heparins attenuated histone-mediated cytotoxicity *in vitro* and improved the survival in a rat model of histone-induced organ dysfunction. *Intensive Care Med Exp*. 2015;3:36.
21. Mycroft-West C, Su D, Elli S, Guimond S, Miller G, Turnbull J, et al. The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 receptor binding domain undergoes conformational change upon heparin binding. *BioRxiv*. 2020:971093. doi: <https://doi.org/10.1101/2020.02.29.2971093>